Why This Matters
More than 50 million American adults who are eligible for colorectal cancer screening have never completed it. The reasons are predictable: colonoscopy requires preparation, sedation, time off work, and a driver. Stool-based tests require collecting samples at home, which many people avoid. The persistently unscreened population represents a major preventable cancer burden, and colorectal cancer is already the second-leading cancer killer in the United States.
Against that backdrop, the American Cancer Society's updated 2026 colorectal cancer screening guidelines now include a blood-based test called Shield, made by Guardant Health, as an official screening option. For people who have declined all other screening methods, a blood draw at a routine doctor's visit now counts. That is meaningful progress.
But buried in the same guidelines is a critical qualification that is being underemphasized in public coverage of this update. Shield is not a preferred option. The ACS explicitly says it is less effective at detecting precancerous polyps than either colonoscopy or stool-based tests. And a positive Shield result is not a diagnosis: it requires a follow-up colonoscopy within six months. Anyone making a screening decision based on the Shield test alone needs to understand what it can and cannot do.
What We Know So Far
The ACS 2026 guideline, published May 27, 2026, in CA: A Cancer Journal for Clinicians, reaffirms the recommendation that average-risk adults begin colorectal cancer screening at age 45 and continue through age 75 for those with a life expectancy greater than 10 years. It is the first major guideline update since 2018.
The preferred screening options remain colonoscopy every 10 years, high-sensitivity stool-based tests (annual guaiac FOBT or FIT, or multitarget stool DNA tests every one to three years), or CT colonography every five years. A new stool-based test using multitarget stool RNA analysis (ColoSense, also called mt-sRNA) was added to the preferred stool category.
The blood-based option, Shield, was added to the guidelines as a recommended but non-preferred test. Specifically, the ACS states: "New blood-based tests are also among the recommended tests, but they are not a preferred option at this time."
Shield was approved by the FDA in 2024 and is covered by Medicare with a three-year testing interval for beneficiaries 45 and older.
Where the Access Situation Stands — and Where the Gaps Are
The Shield test is available through a physician's order and requires only a blood draw during a routine office visit. That accessibility is its primary advantage over all other colorectal cancer screening options. For people who have declined colonoscopy or stool-based testing despite multiple recommendations, the option of a blood test represents a genuine new pathway.
However, as the Colorectal Cancer Alliance notes in its analysis of the updated guidelines, blood-based tests including Shield do not detect precancerous polyps. They detect tumor DNA circulating in the bloodstream, meaning they are better at identifying cancer that has already formed than at finding the precancerous growths that colonoscopy can remove before they become cancer.
That distinction is not minor. Colorectal cancer is most preventable, not merely most detectable, when screening finds and removes precancerous polyps. A blood test that misses polyps is a useful option for people who will not complete other tests, but it is not a substitute for those tests in terms of cancer prevention potential.
The Centers for Medicare and Medicaid Services covers Shield for eligible Medicare beneficiaries on a three-year interval. Coverage under commercial insurance plans varies significantly. The U.S. Preventive Services Task Force (USPSTF) has not yet granted Shield an A or B recommendation, meaning coverage mandates under the Affordable Care Act do not currently apply to private insurers, and some may require out-of-pocket costs for the test.
What Doctors and Experts Say
The ACS guideline update quotes Dr. William Wolf, the lead guideline author, directly: "We need to increase our emphasis on colorectal cancer as a highly preventable disease as much as a treatable one." That framing reflects the tension at the heart of the blood test debate: blood-based screening is better than no screening, but it offers less prevention potential than the options it is explicitly positioned as a fallback for.
The AJMC's analysis of the guideline update notes that timely diagnostic colonoscopy after any positive non-colonoscopy test, ideally within six months, is required to complete the screening episode. Delays in follow-up after a positive blood test create the same risk as delays after a positive stool test: a cancer or advanced polyp is identified but not promptly evaluated.
The Colorectal Cancer Alliance is explicit about the hierarchy: "Blood-based tests are not preferred screening options at this time. People should only use a blood-based test if they are unwilling to get a stool-based test or visual exam."
What the Evidence Shows and What It Does Not
Shield's sensitivity for detecting colorectal cancer is its most validated characteristic. Its sensitivity for detecting advanced precancerous lesions (large polyps that have not yet become cancer) is substantially lower than colonoscopy or high-sensitivity stool-based tests, as documented in the FDA approval data and cited in the ACS guideline itself.
The ACS guideline is transparent about this limitation: blood-based tests are not preferred "primarily because of lower sensitivity for advanced precancerous lesions and stage I colorectal cancers" and because optimal long-term testing intervals for maximum effectiveness have not yet been established.
The CMS-specified three-year interval for Medicare coverage is an administrative decision, not a clinically validated interval based on long-term outcome data.
MedicalDaily Evidence Check
- Source: American Cancer Society 2026 Colorectal Cancer Screening Guideline Update, published May 27, 2026, in CA: A Cancer Journal for Clinicians
- What it shows: Shield blood test is now a recommended colorectal cancer screening option for average-risk adults 45 and older; colonoscopy and stool-based tests remain the preferred options
- What it does not prove: That blood-based testing is equivalent to colonoscopy or stool testing for cancer prevention; the ACS explicitly states it is not preferred and has lower sensitivity for precancerous polyps
-
What readers should know: A positive Shield result requires follow-up colonoscopy within six months; the test is not a substitute for colonoscopy in people willing and able to complete it
Who Faces the Greatest Risk?
The adults most likely to be affected by these updated guidelines include:
- Adults aged 45 to 75 who have not yet completed colorectal cancer screening
- People who have declined colonoscopy due to preparation burden, sedation concerns, or access barriers
- Medicare beneficiaries seeking a covered alternative to colonoscopy
- People with limited access to gastroenterology specialists, where colonoscopy waitlists may be long
People at elevated risk for colorectal cancer, including those with a personal or family history of polyps or colorectal cancer, inflammatory bowel disease, or inherited cancer syndromes such as Lynch syndrome, are not the target audience for average-risk screening guidelines. Those individuals should be discussing high-risk screening protocols directly with their physicians.
Symptoms and Warning Signs to Watch For
Colorectal cancer often has no symptoms in its early stages, which is exactly why screening in asymptomatic people is so important. When symptoms do appear, they may include:
- Blood in the stool, or stools that appear black or tarry
- A change in bowel habits lasting more than a few days, such as diarrhea, constipation, or narrowing of stool
- A feeling that the bowel does not empty completely
- Abdominal discomfort such as cramps, gas, or pain
- Unexplained fatigue or weight loss
These symptoms are not screening indications. They are reasons for immediate clinical evaluation. Anyone experiencing them should contact a clinician promptly rather than scheduling a routine screening test.
What You Can Do Now
- If you are 45 or older and have not completed colorectal cancer screening, speak with your physician about which test is most appropriate given your medical history, risk level, and access to follow-up care.
- If you are interested in the Shield blood test, confirm whether it is covered under your specific insurance plan before requesting the test. Medicare coverage at a three-year interval is established; private insurance coverage varies.
- Understand before taking any screening test that a positive result requires colonoscopy within six months. If access to colonoscopy would be a barrier for you, discuss this with your physician before choosing a blood-based or stool-based test.
-
If you have a family history of colorectal cancer or polyps, you may qualify for screening that begins before age 45 and follows a different schedule. Confirm your personal risk category with a gastroenterologist.
Cost and Access: What Patients Should Know
Under the Affordable Care Act, colorectal cancer screening that has an A or B recommendation from the USPSTF must be covered by private insurers with no cost-sharing for adults 45 and older. Colonoscopy and all USPSTF-recommended stool tests fall in this category. Shield does not yet have a USPSTF A or B rating, so coverage under private insurance plans varies and cost-sharing may apply.
Medicare covers colonoscopy, FIT, and Cologuard (multitarget stool DNA) under Part B with no cost-sharing once the deductible is met, or under specific screening benefit provisions. Medicare covers Shield every three years under Part B for eligible beneficiaries.
For uninsured patients, federally qualified health centers and some community health centers offer reduced-cost colorectal cancer screening. Many states also have colorectal cancer prevention programs that provide low-cost screening for qualifying residents.
What Happens Next
The USPSTF is expected to update its colorectal cancer screening recommendations to account for newer test options, including blood-based ctDNA tests and next-generation stool tests. A USPSTF A or B recommendation for Shield would trigger mandatory commercial insurance coverage and could substantially change how widely the test is used. No specific timeline has been announced for that update.
Longer-term outcome data from large cohorts using blood-based colorectal cancer screening are also being gathered. Those results, expected over the next several years, will determine whether the ACS elevates blood-based tests to preferred status or maintains the current hierarchy.
The Bottom Line
Colorectal cancer screening can prevent cancer, not just detect it, when precancerous polyps are found and removed. The Shield blood test is now officially in ACS screening guidelines for adults 45 and older, but the guidelines explicitly describe it as a non-preferred option for people who decline other tests. For everyone willing and able to complete colonoscopy or a high-sensitivity stool test, those remain the more effective choices. For the millions of eligible adults who have declined all previous screening options, a blood draw is now a real and guideline-supported starting point, with the clear understanding that a positive result requires follow-up colonoscopy within six months.
.png?w=600)
